glatiramer acetate / Generic mfg.  >>  Phase 3
Welcome,         Profile    Billing    Logout  

7 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
glatiramer acetate / Generic mfg.
2008-007162-32: ADVANCED MRI STUDY ON INFLAMMATORY AND DEGENRATIVE DAMAGE IN MULTIPLE SCLEROSIS

Ongoing
3
50
Europe
COPAXONE, AVONEX, COPAXONE, AVONEX
ISTITUTO C. MONDINO
Multiple Sclerosis
 
 
2012-005086-12: Study to investigate the ability of a blood-derived score to select patients with relapsing multiple sclerosis who benefit from treatment with human immune globulin

Ongoing
3
81
Europe
Rebif 44 micrograms, Betaferon 250 microgram/ml, Extavia 250 microgram/ml, Octagam 50 mg/ml, Copaxone 20 mg/ml, Rebif 44 micrograms, Betaferon 250 microgram/ml, Extavia 250 microgram/ml, Octagam 50 mg/ml, Copaxone 20 mg/ml, Rebif 44 micrograms, Betaferon 250 microgram/ml, Extavia 250 microgram/ml
Octapharma AG, Octapharma AG
relapsing multiple sclerosis
 
 
2018-001292-21: Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years Arrêt des traitements de fond à visée immunologique chez les patients de plus de 50 ans ayant une sclérose en plaques secondairement progressive

Not yet recruiting
3
250
Europe
AVONEX, BETAFERON, EXTAVIA, REBIF, PLEDIGRY, COPAXONE, AUBAGIO, TECFIDERA, GILENYA, TYSABRI, IMUREL, NOVATREX, CELLCEPT, ENDOXAN, L03 AB 08, Concentrate for solution for injection, Powder for solution for injection, Solution for injection, Solution for injection in pre-filled syringe, Tablet, Capsule, Concentrate for solution for infusion
CHU de Rennes, CHU de Rennes
Secondary Progressive Multiple Sclerosis Sclérose en plaques secondairement progressive, Secondary Progressive Multiple Sclerosis Sclérose en plaques secondairement progressive, Diseases [C] - Nervous System Diseases [C10]
 
 
LemKids, NCT03368664 / 2016-003100-30: A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT

Active, not recruiting
3
16
Europe, RoW
Alemtuzumab GZ402673, Lemtrada, Glatiramer acetate, Copaxone, Beta-Interferon, Methylprednisolone, Ranitidine, Ceterizine, Dexchlorpheniramine, Paracetamol, Acyclovir, Prednisolone, Diphenydramine, Other H1 antagonist
Genzyme, a Sanofi Company
Multiple Sclerosis
05/21
12/25
2020-004505-32: Study of efficacy and tolerability of ofatumumab vs. First Line disease modifying treatment (DMT) - physician’s choice in the treatment of newly diagnosed relapsing multiple sclerosis (RMS) patients

Ongoing
3
236
Europe
ofatumumab, Glatiramer acetate, Interferon β-1b, Interferon β-1a, Peginterferon β-1a, Teriflunomide, Dimethyl fumarate, OMB157, Solution for injection in pre-filled pen, Solution for injection in pre-filled syringe, Powder and solution for solution for injection, Solution for injection, Solution for infusion in pre-filled syringe, Coated tablet, Gastro-resistant capsule, soft, Kesimpta
Novartis Pharma AG, Novartis Pharma AG
Multiple Sclerosis Sclérose en plaques, Multiple Sclerosis Sclérose en plaques, Diseases [C] - Nervous System Diseases [C10]
 
 
STHENOS, NCT04788615 / 2020-004505-32: Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS

Recruiting
3
186
Europe
Ofatumumab, OMB157, First line DMT, Glatiramer acetate or Interferon or Peg-Interferon beta-1a or Teriflunomide or Dimethyl fumarate or Diroximel fumarate
Novartis Pharmaceuticals, Novartis Pharma AG
Multiple Sclerosis
10/25
01/26
MIST, NCT03133403 / 2012-004165-41: Hematopoietic Stem Cell Therapy for Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy

Recruiting
2/3
5
Europe
Tecfidera (BG12), Gilenya, fingolimod, Tysabri®, natalizumab, Avonex/Betaseron/Copaxone/Rebif, (Avonex®, Betaseron®, Copaxone®, Rebif®), Hematopoietic stem cell transplantation (HSCT)
Sheffield Teaching Hospitals NHS Foundation Trust
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
12/21
12/21

Download Options